| Literature DB >> 29849484 |
Jéssica R Silva1, Beatriz Burger1, Carolina M C Kühl1, Thamiris Candreva1, Mariah B P Dos Anjos1, Hosana G Rodrigues1.
Abstract
Wound healing is an evolutionarily conserved process that is essential for species survival. Wound healing involves a series of biochemical and cellular events that are tightly controlled, divided into 3 concomitant and overlapping phases: inflammation, proliferation, and remodelling. Poor wound healing or a chronic wound represents a silent epidemic that affects billions of people worldwide. Considering the involvement of immune cells in its resolution, recent studies are focused on investigating the roles of immune nutrients such as amino acids, minerals, and fatty acids on wound healing. Among the fatty acids, much attention has been given to omega-6 (ω-6) fatty acids since they can modulate cell migration and proliferation, phagocytic capacity, and production of inflammatory mediators. The present review summarizes current knowledge about the role of ω-6 fatty acids in the wound healing context.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29849484 PMCID: PMC5925018 DOI: 10.1155/2018/2503950
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Figure 1Wound healing process. The illustration shows the inflammatory, proliferative, and remodelling phases of wound healing. Early stages of wound healing include coagulation and activation of inflammatory cells. The proliferative stage involves proliferation of fibroblasts and angiogenesis. The remodelling phase includes restoration of the barrier and contraction of the wound by myofibroblasts. The process is orchestrated by immune cells and growth factors and cytokines and chemokines (listed below) [8]. HF = hair follicle; BV = blood vessels; TNF = tumor necrosis factor; IL-1beta = interleucina 1beta; IL-6 = interleucina 6; ROS = reactive oxygen species; CXCL2 = chemokine (C-X-C motif) ligand 2; IFN-gamma = interferon-gamma; VEGF = vascular endothelial growth factor; TGF-beta = transforming growth factor beta; FGF = fibroblast growth factor; KGF = keratinocyte growth factor; MCP1 = monocyte chemoattractant protein-1; IGF = insulin growth factor; TIMPs = tissue inhibitors of metalloproteinases; MMPs = matrix matalloproteinases; PDGF = platelet-derived growth factor; EGF = epithelial growth factor.
Effects of linoleic (LA) fatty acid.
| Fatty acid | Condition | Study model | Treatment time | Dose/concentration | Molecules associated | Effect in tissue repair | Reference |
|---|---|---|---|---|---|---|---|
| LA | Wound healing | Diabetic Wistar rats | 18 days | 0.22 g/Kg bw (oral administration) | Increased VEGF and ANGPT-2 | Accelerated the inflammatory phase and angiogenesis | [ |
| Pressure ulcers | Healthy humans | 21 days | 1.6 g EFA with LA extracted from sunflower oil (topical application) | NA | Increased hydration and elasticity. | [ | |
| Wound healing | Healthy rats | 12 days | 0.14 g solution with TGs, LA, vitamins A and E, and soy lecithin (topical application) | NA | No effects | [ | |
| Wound healing | Zebrafish | 48 hours | 10–100 | NA | Improved regeneration (100 | [ | |
| CD-1 mice | 11 days | 200, 500, or 1000 | NA | Improved wound healing and formation of new blood vessels (500 and 1000 | |||
| Wound healing | Healthy rats | 11 days | 0.52 | Increased hydroxyproline content | Accelerated wound closure and bleeding time, improved fibrin stabilization, increased migration of fibroblasts, and reduced infiltration of macrophages | [ | |
| Wound healing | Healthy BALB/c mice | 20 days | 30 | Increased NO production | Accelerated tissue repair | [ | |
| Wound healing | Healthy Wistar rats | 24 hours | 300 | Increased total protein and DNA contents and elevated VEGF- | No effect on wound area | [ | |
| Wound healing | Healthy Wistar rats | 5 days | 0.22 g/Kg bw of pure LA (oral administration) | Increased H2O2 and AP-1 and reduced NF- | Accelerated the inflammatory phase | [ | |
| Neutrophil functions | Intraperitoneal neutrophils from healthy Wistar rats | 10 days | 0.11, 0.22, and 0.44 g/kg of bw (oral administration) | Increased L-selectin, IL-1 | Increased leukocyte-endothelium interactions | [ | |
| Neutrophil functions | Intraperitoneal neutrophils from healthy Wistar rats | 20 minutes | 0, 10, 25, 50, 100, and 200 | Increased O2− and H2O2 (50 | Increased ROS | [ | |
| Macrophage functions | Macrophages from healthy Wistar rats | 10 days | 0.22 g/Kg bw (oral administration) | Reduced IL-6, VEGF, and IL-10 | Modulated cytokine production by macrophages | [ |
Essential fatty acids (EFA); triglycerides (TGs); nitric oxide (NO); Deoxyribonucleic acid (DNA); vascular endothelial growth factor (VEGF); interleukin-1β (IL-1β); body weight (bw); hydrogen peroxide (H2O2); activator protein-1 (AP-1); nuclear transcription factor (NF-κB); interleukin-6 (IL-6); angiopoietin-2 (ANGPT-2); cytokine-induced neutrophil chemoattractant-2 (CINC-2αβ); reactive oxygen species (ROS); lipopolysaccharides (LPS); interleukin-10 (IL-10); not analysed (NA).
Effects of conjugated linoleic acid (CLA).
| Fatty acid | Condition | Study model | Treatment time | Dose/concentration | Molecules associated | Effect in tissue repair | Reference |
|---|---|---|---|---|---|---|---|
| CLA | Wound healing | Healthy mice | 2 weeks | 0.5 or 1% of CLA (diet) | Increased CuZnSOD, and MnSOD and reduced pIkB | Increased the antioxidant defences and reduced the wound area (1%) | [ |
| Hairless skin | Mice | 6 hours | 0.25 or 1 mg (topical application) | Reduced NF- | Antitumor (1 mg) | [ | |
| Inflammatory diseases | Bovine PBMC | 24 hours | 100 | Decreased TNF- | Additional studies are needed | [ | |
| Inflammatory diseases | Blood phagocytes isolated from dogs | 24 hours | 10 | Increased TNF- | Increased oxidative burst activity and phagocytic capacity | [ |
CuZn superoxide dismutase (CuZnSOD); Mn superoxide dismutase (MnSOD); cicloxigenase-2 (COX-2); malondialdehyde (MDA); nuclear transcription factor (NF-κB); IκB kinase (IKKα/β); mitogen-activated protein kinase (MAPK); protein kinase B (Akt); tumor necrosis factor α (TNF-α); peripheral blood mononuclear cells (PBMC); not analysed (NA).
Effects of gamma linolenic (GLA) fatty acid.
| Fatty acid | Condition | Study model | Treatment time | Dose/concentration | Molecules associated | Effect in tissue repair | Reference |
|---|---|---|---|---|---|---|---|
| GLA | Acne vulgaris | Healthy humans | 10 weeks | 400 mg (oral administration) | Reduced IL-8 | Reduced lesion number, severity, and inflammation | [ |
| Atopic dermatitis (AD) | Humans | 12 weeks | 320 or 480 mg (oral administration) | NA | Improvement of clinical signs of AD | [ | |
| Macrophage functions | RAW 264.7 macrophages | 100 to 200 | Reduced iNOS, NO, COX-2, pro-IL-1, pI | Decreased inflammation | [ |
Interleukin-8 (IL-8); inducible nitric oxide synthase (iNOS); oxide nitric (NO); cicloxigenase-2 (COX-2); prointerleukin-1 (pro-IL-1); nuclear transcription factor (NF-κB); not analysed (NA)
Effects of arachidonic (AA) fatty acid.
| Fatty acid | Condition | Study model | Treatment time | Dose/concentration | Molecules associated | Effect in tissue repair | Reference |
|---|---|---|---|---|---|---|---|
| AA | Wound healing | hUCB-MSC | 24 hours | 5 or 10 | Increased mTORser2481, Aktser407, PKC | Increased cell migration and angiogenesis (10 | [ |
| Intestinal ischemic injury | Pigs | 10 days | 0.5 or 5% of AA (diet) | Increased PGE2 | Preservation of epithelial barrier (5%) | [ | |
| IBD | Rats | 8 weeks | 0, 5, 35, or 240 mg/Kg of bw (oral administration) | Increased COX-2, LTB4, TXB2, and MPO | Increased inflammation and macrophage infiltration | [ | |
| Angiogenesis | Porcine endothelial cells | 24 hours | 0, 20, 50, 60, and 80 | NA | Increased cell spreading (20 | [ |
Prostaglandin E2 (PGE2); inflammatory bowel disease (IBD); body weight (bw); cicloxigenase-2 (COX-2); leukotriene B4 (LTB4); thromboxane (TXB2); myeloperoxidase (MPO); human umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC); mammalian target of rapamycin complex 1 phosphorylation (mTORser2481); protein kinase B (Aktser407); phosphorylates protein kinase Cζ (PKCζ); matrix metalloproteinases (MMPs); not analysed (NA).
Figure 2Effects of linoleic acid (LA), conjugated linoleic acid (CLA), gamma linolenic acid (GLA), and arachidonic acid on wound healing phases.